Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$11.55 USD
+0.03 (0.26%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.35 -0.20 (-1.73%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ATRA 11.55 +0.03(0.26%)
Will ATRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRA
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for ATRA
Atara Biotherapeutics (ATRA) Shares Surge After Priority Review Grant
Atara gets FDA priority review for Tabelecleucel application
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics ...
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel (ATRA) | ATRA Stock News
Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA